Category: 2021

Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. New clinical abstract on SEL24(MEN1703) also available.

Read More

Ryvu Therapeutics Reports First Quarter 2021 Financial Results

Read More

Ryvu Therapeutics appoints Vatnak Vat-Ho as Chief Business Officer

Read More

Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Read More

Ryvu Therapeutics at BIO-Europe Spring

Read More

Ryvu Therapeutics reports financial results for 2020

Read More

Ryvu Therapeutics awarded in the Stock Exchange Company of the Year competition

Read More

Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2021 Virtual Annual Meeting

Read More

Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR

Read More

Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland

Read More

Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors

Read More